Press release
26.07.2024 To the attention of interested persons EMA advises about risks of using weight loss medicine Mysimba with opioids download […]
Press release
24.07.2024 To the attention of interested persons EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines […]
Important notification
17.07.2024 To the attention of interested persons Announcement regarding professional training and instruction courses for staff with specific duties of […]
Press release
12.07.2024 To the attention of interested persons Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 July 2024 download […]
Important notification
10.07.2024 To the attention of all stakeholders We inform you that on 9 July 2024, the European Commission published Regulation […]
Press release
28.06.2024 To the attention of interested persons Hydroxyprogesterone caproate medicines to be suspended from the EU market download document …
Press release
28.06.2024 To the attention of interested persons EMA recommends revoking conditional marketing authorisation for Ocaliva download document …
Press release
28.06.2024 To the attention of interested persons EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna download document […]
Press release
26.06.2024 To the attention of interested persons EU actions to tackle shortages of GLP-1 receptor agonists download document …
Important notification
18.06.2024 To the attention of all Marketing Authorisation Holders / Legal representatives of Marketing Authorisation Holders As of 01.07.2024, temporary […]